{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:09:46Z","timestamp":1790442586148,"version":"4.1.0"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K17166"],"award-info":[{"award-number":["JP19K17166"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19im0210819"],"award-info":[{"award-number":["JP19im0210819"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Carbonic anhydrase-IX (CA-IX) is attracting much attention as a target molecule for cancer treatment since high expression of CA-IX can lead to a poor prognosis of patients. We previously reported low-molecular-weight <jats:sup>111<\/jats:sup>In\/<jats:sup>90<\/jats:sup>Y complexes with a bivalent ureidosulfonamide scaffold ([<jats:sup>111<\/jats:sup>In\/<jats:sup>90<\/jats:sup>Y]In\/Y-US2) as cancer radiotheranostic agents for single photon emission computed tomography and radionuclide-based therapy targeting CA-IX. Here, we applied the US2 platform to positron emission tomography (PET) imaging and pharmacological therapy targeting CA-IX high-expressing tumors by introducing <jats:sup>68<\/jats:sup>Ga and <jats:sup>nat<\/jats:sup>In, respectively. In an <jats:italic>in vitro<\/jats:italic> cell binding assay, [<jats:sup>67<\/jats:sup>Ga]Ga-US2, an alternative complex of [<jats:sup>68<\/jats:sup>Ga]Ga-US2 with a longer half-life, markedly bound to CA-IX high-expressing (HT-29) cells compared with low-expressing (MDA-MB-231) cells. In a biodistribution study with HT-29 and MDA-MB-231 tumor-bearing mice, [<jats:sup>67<\/jats:sup>Ga]Ga-US2 showed accumulation in the HT-29 tumor (3.81% injected dose\/g at 60 min postinjection) and clearance from the blood pool with time. PET with [<jats:sup>68<\/jats:sup>Ga]Ga-US2 clearly visualized the HT-29 tumor in model mice at 60 min postinjection. In addition, the administration of [<jats:sup>nat<\/jats:sup>In]In-US2 to HT-29 tumor-bearing mice led to tumor growth delay and prolonged mouse survival, while no critical toxicity was observed. These results indicate that [<jats:sup>68<\/jats:sup>Ga]Ga-US2 and [<jats:sup>nat<\/jats:sup>In]In-US2 may be useful imaging and therapeutic agents targeting CA-IX, respectively, and that US2 may serve as an effective cancer theranostic platform utilizing CA-IX.<\/jats:p>","DOI":"10.1371\/journal.pone.0243327","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:13:31Z","timestamp":1607559211000},"page":"e0243327","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["PET imaging and pharmacological therapy targeting carbonic anhydrase-IX high-expressing tumors using US2 platform based on bivalent ureidosulfonamide"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7073-9084","authenticated-orcid":true,"given":"Shimpei","family":"Iikuni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"pone.0243327.ref001","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.febslet.2007.06.018","article-title":"Oxygen, a source of life and stress","volume":"581","author":"MC Brahimi-Horn","year":"2007","journal-title":"FEBS Lett"},{"key":"pone.0243327.ref002","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature00767","article-title":"Structural basis for the recognition of hydroxyproline in HIF-1\u03b1 by pVHL","volume":"417","author":"WC Hon","year":"2002","journal-title":"Nature"},{"key":"pone.0243327.ref003","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-\u03b1 to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"P Jaakkola","year":"2001","journal-title":"Science"},{"key":"pone.0243327.ref004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10555-007-9058-y","article-title":"Hypoxia and cancer","volume":"26","author":"GL Semenza","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"pone.0243327.ref005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"CT Supuran","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"pone.0243327.ref006","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?","volume":"112","author":"V Alterio","year":"2012","journal-title":"Chem Rev"},{"key":"pone.0243327.ref007","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"PH Maxwell","year":"1999","journal-title":"Nature"},{"key":"pone.0243327.ref008","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature04871","article-title":"Hypoxia signalling in cancer and approaches to enforce tumour regression","volume":"441","author":"J Pouyssegur","year":"2006","journal-title":"Nature"},{"key":"pone.0243327.ref009","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/82113","article-title":"Targeting tumors through the HIF system","volume":"6","author":"PJ Ratcliffe","year":"2000","journal-title":"Nat Med"},{"key":"pone.0243327.ref010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","article-title":"Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy","volume":"58","author":"AB Stillebroer","year":"2010","journal-title":"Eur Urol"},{"key":"pone.0243327.ref011","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tips.2006.09.002","article-title":"Targeting tumor-associated carbonic anhydrase IX in cancer therapy","volume":"27","author":"A Thiry","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"pone.0243327.ref012","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/ijc.22436","article-title":"HIF-1\u03b1 and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome","volume":"120","author":"C Trastour","year":"2007","journal-title":"Int J Cancer"},{"key":"pone.0243327.ref013","doi-asserted-by":"crossref","first-page":"27799","DOI":"10.1074\/jbc.M800938200","article-title":"Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes","volume":"283","author":"M Hilvo","year":"2008","journal-title":"J Biol Chem"},{"key":"pone.0243327.ref014","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","article-title":"The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond","volume":"38","author":"S Pastorekova","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"pone.0243327.ref015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jcp.22400","article-title":"pH control mechanisms of tumor survival and growth","volume":"226","author":"SK Parks","year":"2011","journal-title":"J Cell Physiol"},{"key":"pone.0243327.ref016","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1038\/onc.2010.455","article-title":"New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation","volume":"29","author":"P Swietach","year":"2010","journal-title":"Oncogene"},{"key":"pone.0243327.ref017","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.08.002","article-title":"Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use","volume":"31","author":"J Pastorek","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"pone.0243327.ref018","first-page":"3953s","article-title":"Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with 131I or 111In: an intrapatient comparison","volume":"9","author":"AH Brouwers","year":"2003","journal-title":"Clin Cancer Res"},{"key":"pone.0243327.ref019","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","article-title":"Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial","volume":"31","author":"CR Divgi","year":"2013","journal-title":"J Clin Oncol"},{"key":"pone.0243327.ref020","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.109.073189","article-title":"PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors","volume":"51","author":"BA Hoeben","year":"2010","journal-title":"J Nucl Med"},{"key":"pone.0243327.ref021","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.eururo.2013.02.022","article-title":"Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma","volume":"63","author":"CH Muselaers","year":"2013","journal-title":"Eur Urol"},{"key":"pone.0243327.ref022","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00259-019-04358-9","article-title":"Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma","volume":"46","author":"SR Verhoeff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0243327.ref023","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1021\/jm300529u","article-title":"Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts","volume":"55","author":"RG Gieling","year":"2012","journal-title":"J Med Chem"},{"key":"pone.0243327.ref024","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2967\/jnumed.115.170514","article-title":"A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo","volume":"57","author":"N Krall","year":"2016","journal-title":"J Nucl Med"},{"key":"pone.0243327.ref025","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1039\/C4SC00685B","article-title":"A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice","volume":"5","author":"N Krall","year":"2014","journal-title":"Chem Sci"},{"key":"pone.0243327.ref026","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2967\/jnumed.114.153288","article-title":"Trimeric radiofluorinated sulfonamide derivatives to achieve in vivo selectivity for carbonic anhydrase IX-targeted PET imaging","volume":"56","author":"J Lau","year":"2015","journal-title":"J Nucl Med"},{"key":"pone.0243327.ref027","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acs.molpharmaceut.5b00934","article-title":"PET imaging of carbonic anhydrase IX expression of HT-29 tumor xenograft mice with 68Ga-labeled benzenesulfonamides","volume":"13","author":"J Lau","year":"2016","journal-title":"Mol Pharm"},{"key":"pone.0243327.ref028","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1021\/acs.bioconjchem.6b00271","article-title":"Evaluation of nonpeptidic ligand conjugates for SPECT imaging of hypoxic and carbonic anhydrase IX-expressing cancers","volume":"27","author":"PC Lv","year":"2016","journal-title":"Bioconjug Chem"},{"key":"pone.0243327.ref029","doi-asserted-by":"crossref","first-page":"56471","DOI":"10.18632\/oncotarget.10602","article-title":"[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma","volume":"7","author":"I Minn","year":"2016","journal-title":"Oncotarget"},{"key":"pone.0243327.ref030","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1021\/jm101541x","article-title":"Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis","volume":"54","author":"F Pacchiano","year":"2011","journal-title":"J Med Chem"},{"key":"pone.0243327.ref031","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11307-015-0831-y","article-title":"[18F]VM4-037 microPET imaging and biodistribution of two in vivo CAIX-expressing tumor models","volume":"17","author":"SG Peeters","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"pone.0243327.ref032","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1021\/acs.jmedchem.6b00623","article-title":"Synthesis and in vivo biological evaluation of 68Ga-labeled carbonic anhydrase IX targeting small molecules for positron emission tomography","volume":"59","author":"D Sneddon","year":"2016","journal-title":"J Med Chem"},{"key":"pone.0243327.ref033","doi-asserted-by":"crossref","first-page":"33733","DOI":"10.18632\/oncotarget.5254","article-title":"Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor","volume":"6","author":"X Yang","year":"2015","journal-title":"Oncotarget"},{"key":"pone.0243327.ref034","first-page":"S53","article-title":"[177Lu]XYIMSR-01, a theranostic for targeting carbonic anhydrase IX","volume":"57","author":"I Minn","year":"2016","journal-title":"J Nucl Med"},{"key":"pone.0243327.ref035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/med.10025","article-title":"Carbonic anhydrase inhibitors","volume":"23","author":"CT Supuran","year":"2003","journal-title":"Med Res Rev"},{"key":"pone.0243327.ref036","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0960-894X(03)00091-X","article-title":"Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides","volume":"13","author":"D Vullo","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"pone.0243327.ref037","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00109-017-1590-9","article-title":"Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis","volume":"95","author":"E Andreucci","year":"2017","journal-title":"J Mol Med (Berl)"},{"key":"pone.0243327.ref038","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","article-title":"Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors","volume":"71","author":"Y Lou","year":"2011","journal-title":"Cancer Res"},{"key":"pone.0243327.ref039","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3727\/096504017X14965111926391","article-title":"Inhibition of carbonic Aanhydrase IX by ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity","volume":"26","author":"A Riemann","year":"2018","journal-title":"Oncol Res"},{"key":"pone.0243327.ref040","doi-asserted-by":"crossref","first-page":"8271","DOI":"10.1021\/jm200983e","article-title":"Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors","volume":"54","author":"N Touisni","year":"2011","journal-title":"J Med Chem"},{"key":"pone.0243327.ref041","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1021\/ja809683v","article-title":"Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors","volume":"131","author":"A Maresca","year":"2009","journal-title":"J Am Chem Soc"},{"key":"pone.0243327.ref042","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/molecules23010153","article-title":"Novel 6- and 7-substituted coumarins with inhibitory action against lipoxygenase and tumor-associated carbonic anhydrase IX","volume":"23","author":"A Peperidou","year":"2018","journal-title":"Molecules"},{"key":"pone.0243327.ref043","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1021\/acs.jmedchem.5b00523","article-title":"6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells","volume":"58","author":"A Grandane","year":"2015","journal-title":"J Med Chem"},{"key":"pone.0243327.ref044","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1016\/j.bmc.2013.05.032","article-title":"7-Substituted-sulfocoumarins are isoform-selective, potent carbonic anhydrase II inhibitors","volume":"21","author":"M Tanc","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"pone.0243327.ref045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1021\/jm301625s","article-title":"Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases","volume":"56","author":"K Tars","year":"2013","journal-title":"J Med Chem"},{"key":"pone.0243327.ref046","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.7150\/thno.20982","article-title":"Cancer radiotheranostics targeting carbonic anhydrase-IX with 111In- and 90Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy","volume":"8","author":"S Iikuni","year":"2018","journal-title":"Theranostics"},{"key":"pone.0243327.ref047","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ejmech.2013.10.027","article-title":"Development and biological evaluation of 99mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers","volume":"71","author":"V Akurathi","year":"2014","journal-title":"Eur J Med Chem"},{"key":"pone.0243327.ref048","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.nucmedbio.2010.02.006","article-title":"Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia","volume":"37","author":"V Akurathi","year":"2010","journal-title":"Nucl Med Biol"},{"key":"pone.0243327.ref049","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bmcl.2018.01.060","article-title":"Acetazolamide-based [18F]-PET tracer: In vivo validation of carbonic anhydrase IX as a sole target for imaging of CA-IX expressing hypoxic solid tumors","volume":"28","author":"KN More","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"pone.0243327.ref050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jinorgbio.2018.04.009","article-title":"Evaluation of 99mTc-sulfonamide and sulfocoumarin derivatives for imaging carbonic anhydrase IX expression","volume":"185","author":"M Nakai","year":"2018","journal-title":"J Inorg Biochem"},{"key":"pone.0243327.ref051","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/14756366.2013.773994","article-title":"Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography","volume":"29","author":"J Pan","year":"2014","journal-title":"J Enzyme Inhib Med Chem"},{"key":"pone.0243327.ref052","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/14756366.2017.1308928","article-title":"Design, synthesis and evaluation of 18F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging","volume":"32","author":"Z Zhang","year":"2017","journal-title":"J Enzyme Inhib Med Chem"},{"key":"pone.0243327.ref053","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13550-016-0189-4","article-title":"Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging","volume":"6","author":"C M\u00fcller","year":"2016","journal-title":"EJNMMI research"},{"key":"pone.0243327.ref054","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/(SICI)1521-3765(19990702)5:7<1974::AID-CHEM1974>3.0.CO;2-X","article-title":"Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy","volume":"5","author":"A Heppeler","year":"1999","journal-title":"Chem Eur J"},{"key":"pone.0243327.ref055","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/cr900325h","article-title":"Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease","volume":"110","author":"TJ Wadas","year":"2010","journal-title":"Chem Rev"},{"key":"pone.0243327.ref056","first-page":"89","article-title":"The expression of G250\/mn\/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells","volume":"7","author":"G Li","year":"2001","journal-title":"Clin Cancer Res"},{"key":"pone.0243327.ref057","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-94-007-7359-2_10","article-title":"Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment","volume":"75","author":"E Oosterwijk","year":"2014","journal-title":"Subcell Biochem"},{"key":"pone.0243327.ref058","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"M Eder","year":"2012","journal-title":"Bioconjug Chem"},{"key":"pone.0243327.ref059","doi-asserted-by":"crossref","first-page":"127255","DOI":"10.1016\/j.bmcl.2020.127255","article-title":"Synthesis and evaluation of indium-111-labeled imidazothiadiazole sulfonamide derivative for single photon emission computed tomography imaging targeting carbonic anhydrase-IX","volume":"30","author":"S Iikuni","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"pone.0243327.ref060","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1002\/anie.201310709","article-title":"A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors","volume":"53","author":"N Krall","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"key":"pone.0243327.ref061","doi-asserted-by":"crossref","first-page":"24856","DOI":"10.18632\/oncotarget.4498","article-title":"Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models","volume":"6","author":"C Ward","year":"2015","journal-title":"Oncotarget"},{"key":"pone.0243327.ref062","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/ijc.31042","article-title":"Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer","volume":"142","author":"JL Bryant","year":"2018","journal-title":"Int J Cancer"},{"key":"pone.0243327.ref063","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/14756366.2018.1532419","article-title":"The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy","volume":"34","author":"E Andreucci","year":"2019","journal-title":"J Enzyme Inhib Med Chem"},{"key":"pone.0243327.ref064","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1021\/jm4009532","article-title":"Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides\/sulfamides\/sulfamates","volume":"56","author":"M Rami","year":"2013","journal-title":"J Med Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:13:56Z","timestamp":1607559236000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243327"}},"subtitle":[],"editor":[{"given":"Pradeep K.","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":64,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0243327","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]}}}